Cancer Detection
The major focus of Dr. Epstein's laboratory
research is the development of novel reagents for the detection
and treatment of human cancers. Monoclonal antibodies directed
against human malignant lymphomas and solid tumors have
demonstrated an ability to target and treat cancers in both
animal models and in humans. Newer methods are under development
which enhance the binding and accumulation of radiolabeled
monoclonal antibodies in tumors by altering the vascular
physiology of tumor vessels. When used as a pre-treatment, these
immunoconjugates produce a localized vascular leakage at the
tumor site, and enable a three-fold increase in the delivery of
radiolabeled monoclonal antibodies to the tumor compared to
untreated controls. In addition, improved methods of antibody
delivery are under development using avidin- biotin. Based on
these studies, genetic engineering techniques are now being
applied to produce chimeric monoclonal antibodies and novel
immunoconjugate fusion proteins for cancer therapy. The studies
have also generated several new approaches for the
radioimmunotherapy of human cancers and have resulted in the
initiation of human clinical trials.
|
Search: [ current | former scholar ] [ current | awarded institution ] [ quick search ]
